Explore the ACTIV-2 trial's efforts to develop effective COVID-19 treatments in this informative 22-minute lecture by Dr. Kara Chew, Assistant Clinical Professor of Medicine at UCLA. Gain insights into the global and local impact of COVID-19, including case numbers, mortality rates by age, race, and ethnicity, and the disease's progression. Learn about current interventions, symptoms, and treatments. Discover the ACTIV initiative's goals, leadership, and eligibility criteria for the trial. Understand the importance of participant numbers, the types of agents being tested, and the role of monoclonal antibodies in fighting the virus. Delve into the workings of antibody treatments and their potential in combating COVID-19. Conclude with a call to action to spread awareness about this crucial research.
Working Towards an Effective Treatment for COVID-19 - The ACTIV-2 Trial by Kara Chew, MD, MS
University of California, Los Angeles via YouTube
Overview
Syllabus
Introduction
COVID19 Impact
COVID19 Cases Worldwide
COVID19 Cases in LA
Deaths by Age
Deaths by Race
Deaths by ethnicity
Course of COVID
Interventions
Symptoms
Treatment
Rise Above COVID
What is ACTIV
ACTIV2 Leadership
Eligibility Criteria
Risk Factors
How will we tell if the drugs work
How many participants do we need
What are the agents in the trial
What are monoclonal antibodies
How do monoclonal antibodies work
Current antibody in the trial
Spread the Word
Taught by
UCLA Health
Tags
Related Courses
-
COVID-19 - A clinical update
-
COVID-19 Vaccines and Treatments: Development, Challenges, and Future Outlook
-
The COVID-19 Pandemic – Sequencing: Impacts on Public Health
-
The HIV and COVID-19 Global Pandemics - Lessons for Responding to Both Viruses
-
Convalescent Plasma for the Treatment of COVID-19 – Presented by Professor David Roberts
